Navigation Links
vProtect(TM) Luminal Shield Stabilizes Life-Threatening Plaque
Date:1/15/2009

Healthy Vessel Seen in 6-Month Follow-up Exam on First Patient to Receive Preventive Treatment for Vulnerable Plaque

ROTTERDAM, Netherlands and DOYLESTOWN, Pa., Jan. 15 /PRNewswire/ -- The first patient receiving focal preventive treatment for vulnerable plaque recently underwent a 6-month follow-up examination that revealed successful stabilization of the target plaque. The interventional cardiology team led by Professor Patrick W. Serruys, MD, PhD, of Erasmus University, placed a vProtect(TM) Luminal Shield in the left anterior descending (LAD) coronary artery of the patient at Erasmus Medical Center in Rotterdam in June of 2008. The 64-year-old man is enrolled in SECRITT I, a pilot study designed to evaluate the vProtect(TM) Luminal Shield as a treatment for vulnerable plaques--"silent" atherosclerotic deposits in the coronary arteries that do not produce symptoms until they rupture with potentially fatal consequences.

To date, the treated artery demonstrated excellent blood flow and healing. As part of the healing process the Shield is now covered by a thin layer of tissue, incorporating it into the arterial wall. This is a hallmark of a successful implant and demonstrated that the Shield performed much better than would be expected for traditional bare metal stents and comparable to the first generation of drug-eluting stents.

"The self-expanding vProtect(TM) Luminal Shield minimizes injury on deployment enabling safe placement over rupture-prone vulnerable plaques," said Patricia Scheller, CEO of Prescient Medical, the manufacturer of the vProtect(TM) Luminal Shield. "Given that there are more than 500,000 sudden cardiac deaths in the US, and more than 300,000 in Europe each year, we are pleased that our device addresses untreated vulnerable plaques, the culprit in a majority of sudden cardiac deaths."

Patients enrolled in SECRITT I have been referred to the cath lab for
'/>"/>

SOURCE Prescient Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sureshield Coatings Company Established to Market Industry-Leading Portfolio of Advanced Coatings for Metal Surfaces
2. Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA Superbug
3. Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology
4. Blue Cross and Blue Shield of Texas Launches an Integrated Medical-Dental Health Program
5. Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers
6. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals
7. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device
8. SyntheMed Announces FDA Clearance of SinusShield(TM)
9. Biomatricas RNAstable(TM) Stabilizes RNA at Room Temperature
10. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
11. Atrial Fibrillation Month - StopAfib.org Announces September Focus on Life-Threatening Irregular Heartbeat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 LayerBio ... for ophthalmology and wound care. The National Eye Institute ... awarded LayerBio a Phase I SBIR grant to develop ... Cataracts are the most common cause of vision loss ... of blindness worldwide. According to Dr. Ken Mandell, LayerBio’s ...
(Date:12/19/2014)... The empty capsules market is experiencing growth ... technological innovations in the empty capsules market. The ... growth of the empty capsules market. , Get ... of Report , The report will enrich both ... to gauge the pulse of the market which ...
(Date:12/19/2014)... NEW YORK , Dec. 18, 2014 ... novel therapies for the treatment of chronic pain, announced ... held today. "This was a transformational year ... a promising future for our company," said Sergio ... past year, we have executed on key financial, human ...
(Date:12/17/2014)... BASKING RIDGE, N.J. (PRWEB) December 17, 2014 ... Ipsen (Euronext: IPN; ADR: IPSEY), ... 120 mg (referred to as Somatuline®) was approved ... for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) ... differentiated, locally advanced or metastatic disease to improve ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... SupraNet Communications, Inc. , an Internet service provider, ... infrastructure, allowing them to provide Internet services to businesses ... options. , ,The new OC12 from Charter Business ... businesses throughout the southern half of state where Charter ...
... write about these days stirs as much feedback as my ... blog tools, search, social networks, and syndication technologies. , ,Over ... of social networks to a cautious blogger, and now an ... disruptive force that is fundamentally changing communications on every facet. ...
... has received a $500,000 federal research grant, the ... II small-business innovation research grant from the National ... treatment. The funding complements the $100,000 phase I grant ... , ,According to Sal Braico, ConjuGons chief operating officer, ...
Cached Biology Technology:Rural Wisconsin businesses gain high-speed net access 2Changing perspectives on social networks 2Changing perspectives on social networks 3ConjuGon receives $500,000 to battle bacteria 2
(Date:11/21/2014)... , November 18, 2014 According ... Market by Systems (Video, RFID, Access Control, Intrusion Detection, ... Hotels, Banks, Government), Component Service Geography - Global Forecasts ... Market is projected to be around $25 Billion in ... 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... 2014   Atmel® Corporation (NASDAQ: ... touch technology solutions, today launched the industry,s first family ... widest V cc range from 1.7V to 5.5V. ... I 2 C bus communication speeds, and are available ... them ideal for consumer, industrial, computer, and medical applications. ...
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... Reproductive medicine is one of today,s most exciting ... of medical ,firsts, new rulings by regulatory bodies or ... in the field, ethicists, legislators, the media and the ... All sessions are open to journalists and registration is ...
... It might sound like a mashup of monster movies, ... attacked its prey, reconstructing a killing that took place 4 ... is incredibly rare, but by careful, forensic-style analysis of bite ... based in Pisa, Italy, have reconstructed the events that led ...
... , This release is available in French . ... Dr. Hanadi Sleiman has achieved a major breakthrough in the development ... drugs to specific diseased cells. Sleiman explains that the research involves ... used as the genetic code for life, it becomes a kind ...
Cached Biology News:ESHRE Annual Meeting, June 27-30 in Rome 2Jaws -- 4 million B.C. 2
...
... Product Rabbit polyclonal to JNK1 (phospho T183 ... to an internal domain containing phosphorylated T183/Y185. ... and Rat. Not yet tested in other species. ... several subgroups, including the ERK, JNK, and p38 ...
Dako Target Retrieval Solution, Citrate pH 6 (x 10) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
... solid. Increases the expression of glutathione peroxidase. ... 2 O. Unstable in aqueous solutions; reconstitute ... 3211-76-5, M.W. 196.1. References: Merck Index ... A.F. 1995. Biochem. J. 306, ...
Biology Products: